(Q33398261)

26 July 2017

A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors (English)

1 reference

26 July 2017

phase II clinical trial

0 references

1 reference

F Balis

5

0 references

author name string

P C Adamson

1

1 reference

26 July 2017

S Zimm

2

1 reference

26 July 2017

A H Ragab

3

1 reference

26 July 2017

S M Steinberg

4

1 reference

26 July 2017

B A Kamen

6

1 reference

26 July 2017

T J Vietti

7

1 reference

26 July 2017

A Gillespie

8

1 reference

26 July 2017

D G Poplack

9

1 reference

26 July 2017

1 January 1990

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

1 reference

26 July 2017

26

1 reference

26 July 2017

5

1 reference

26 July 2017

343-344

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02897290

26 July 2017

0 references

cites work

A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine

1 reference

12 December 2020

Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered?

1 reference

12 December 2020

COMPARATIVE CLINICAL TOXICITY OF 6-MERCAPTOPURINE (NSC-755)-1 AND 6-MERCAPTOPURINE RIBONUCLEOSIDE (NSC-4911)-2 ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH ADVANCED CANCER

1 reference

12 December 2020

Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion

1 reference

12 December 2020

6-mercaptopurine (NSC-755) given intravenously at weekly intervals to patients with advanced cancer

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02897290

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference